FDA's Francis R.W. Godwin (CDER) and Kathleen Jones, PhD (CBER) detail a record pace of drug warning letters and the CGMP deficiencies most commonly cited in biologics facility inspections.
|Articles|September 1, 2016
A leader in BioPharma Product Testing
Advertisement
As a member of Eurofins’ BioPharma Product Testing Group-the largest network of harmonized bio/pharmaceutical GMP product testing laboratories worldwide-Eurofins Lancaster Laboratories supports all functional areas of bio/pharmaceutical manufacturing, including method development, microbiology, process validation and quality control throughout all stages of the drug development process.
Visit our booth at AAPS for a chance to win an Apple Watch.
2425 New Holland Pike, Lancaster, PA 17601
tel. 717.656.2300
AAPS Booth # 1221
Advertisement
Related to this article
Sanofi's Dr Jack Prior detailed a data maturity framework for biologics manufacturing, while FDA and Gilead panelists debated risk-based AI validation.
FDA's consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.
Inebilizumab (Uplizna) cut MG-ADL scores by 1.9 points versus placebo, supporting its approval in Japan for myasthenia gravis.
Regulatory approvals, trial data, and major licensing deals in 2026 are accelerating subcutaneous biologics, cutting patient burden and reshaping biopharma strategy.
Today’s biopharma news highlights GSK’s myeloma strategy, Insilico’s AI longevity research, and innovations that may improve future treatment outcomes.
As data volumes explode, clinical data harmonization, hybrid cloud, and AI are reshaping biopharma IT into the industry's core growth engine.
Insilico's Longevity Vaccines use circular mRNA to arm T cells against aging's earliest culprit cells, starting with immune rejuvenation.
Advertisement
Advertisement